Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
116results about How to "Reduce cell death" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Buffer solution for electroporation and a method comprising the use of the same
InactiveUS20050064596A1High transfection efficiencyReduce cell deathPeptide/protein ingredientsGenetic material ingredientsElectroporationIon
The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an electric current and a buffer solution. The inventive buffer solution has a buffering capacity of at least 20 mmol*I−1*pH−1 and an ionic strength of at least 200 mmol*I−1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25° C. The use of a buffer solution of this type in the corresponding method allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in said buffer solution.
Owner:LONZA COLOGNE
Cell culture treatment apparatus and cell culture treatment method
InactiveUS20080057561A1Simply and efficiently collectReduce cell deathBioreactor/fermenter combinationsBiological substance pretreatmentsBiologyCultured Cell Line
The present invention provides a cell culture treatment device for culturing, treating and collecting cells, which includes a flow path, a cell-retaining section, a solution inlet, a solution outlet, a cell collection port and a lid. The present invention also provides an device for easily, efficiently separating and collecting the cells thereby in a short period of time, and provides a method therefor.
Owner:CANON KK
P53 inhibitors and therapeutic use of the same
InactiveUS6982277B2Reducing and eliminating deathInhibitory activityOrganic active ingredientsBiocideDiseaseSurgery
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
InactiveUS7060270B2Cell deathReduce cell deathImmunoglobulins against animals/humansAntibody ingredientsDiseaseFibril
This invention provides methods and compositions for the detection, diagnosis and treatment of amyloid-associated diseases, in particular, diseases comprising deposition of amyloid assemblies, fibrils, filaments, tangles, or plaques. A preferred composition comprises monoclonal antibodies that specifically bind amyloid proteins, peptides or fragments and change the conformation.
Owner:DIAGENICS INT CORP
Method, Device and System for Targetted Cell Lysis
ActiveUS20130261683A1High permittivityIrreversible electroporationElectrotherapySurgical instrument detailsElectric fieldBiology
A method, device and system employs particles, such as nanoparticles, and an electric or electro-magnetic field, to cause cell death in target cells by non-thermal means. The method of causing targeted cell death comprises the steps of: introducing a particle to the interior of a target cell and exposing the target cell to a transient electromagnetic field for a sufficient time interval in order to cause cell death. The invention overcomes problems associated with similar methods as a result of the fact that a smaller electric field is applied because the particle enhances the effect of the electric field in its immediate vicinity, so reducing the field strength needed to achieve cell lysis and thereby reducing the risk of damage to healthy cells that may be in its vicinity. Apparatus for performing the method; as well as techniques of delivering particles and for producing particles are also described.
Owner:BIOVICES IPR HLDG AS +1
Cell transplantation
ActiveUS20100104542A1Avoid damageReduce cell deathBiocideMicrobiological testing/measurementChemical compositionFat grafting
The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer / cell compositions for cell transplantation.
Owner:THE GENERAL HOSPITAL CORP
Antagonists of a non-selective cation channel in neural cells
InactiveUS20100092469A1Reduce mortalityReduces stroke sizeBiocideNervous disorderDiseaseNervous system
The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and / or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and / or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and / or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Therapeutic agents targeting the NCCa-ATP channel and methods of use thereof
ActiveUS20060100183A1Reduces and decrease and inhibits activationInhibition is effectiveBiocideNervous disorderMedicineNeuron
The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal cord injury.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
CELL CULTURE HYDROGEL WITH pH INDICATOR
InactiveUS20090190135A1Good biocompatibilityHigh water contentMaterial analysis by observing effect on chemical indicatorCulture processNon invasiveD-Glucose
The invention provides devices, compositions and methods for maintaining conditions in a cell culture and for measurement of conditions in the cell culture. In particular, the invention provides hydrogel materials, apparatus and methods for several non-invasive techniques of maintaining glucose and pH levels in cell cultures at near-optimal levels and the non-invasive measurement of pH levels in cell cultures.
Owner:UNIVERSITY OF MASSACHUSETTS LOWELL
p53 Inhibitors and therapeutic use of the same
InactiveUS20050222224A1Reducing and eliminating deathInhibitory activityBiocideNervous disorderDiseaseSurgery
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases
InactiveUS20090209618A1Treating and preventing neoplasiaReduced activityCompound screeningBiocideMedicinePyruvate dehydrogenase activity
The invention provides therapeutic and prophylactic compounds and methods for altering the activity of pyruvate dehydrogenase kinase (e.g. PDK1, PDK2, PDK3, PDK4). Such therapies are useful for the treatment of neoplasia. The invention further provides therapeutic and prophylactic compounds and methods of altering pyruvate dehydrogenase activity to treat or prevent cell death related to ischemia.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Formulations and methods for lyophilization and lyophilates provided thereby
ActiveUS8277845B2Reduce solubilityReduced stabilityAntibacterial agentsBiocideSolubilityFreeze-drying
The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
Owner:REMEDY PHARMA
Dimeric Smac Mimetics
InactiveUS20110195043A1Reduce cell deathReduce cell proliferationAntipyreticAnalgesicsSmac mimeticsDisease
The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
Owner:JOYANT PHARMA INC
Method of preventing fat graft resorption by administering fat-derived cells and poloxamer P 188
Owner:THE GENERAL HOSPITAL CORP
Use of AAV replication machinery for improved protein production
ActiveUS9115373B2Increase viable life-spanReduce cell deathAnimal cellsBryophytesBiotechnologyGene product
The present invention provides a method for enhanced production of a gene product of interest in a cell, using the AAV replication machinery. The present invention further relates to a cell for use in the method of the invention and a non-human transgenic animal or a transgenic plant comprising a cell of the invention.
Owner:UNIQURE IP BV
Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
ActiveUS20160362658A1Reduce cell deathFacilitated DiffusionViral antigen ingredientsMammal material medical ingredientsT lymphocyteT cell
The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and / or that employ a particular bioreactor having a gas permeable membrane.
Owner:BAYLOR COLLEGE OF MEDICINE +1
Methods of inhibiting photoreceptor apoptosis
ActiveUS8343931B2Enhance photoreceptor survivalImprove survivalSenses disorderNervous disorderApoptosisCancer research
Owner:RGT UNIV OF MICHIGAN
Compositions and methods for cardiac tissue repair
ActiveUS20120157381A1Reduce tissue damageImprove heart functionPeptide/protein ingredientsAntipyreticProgenitorTissue repair
The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.
Owner:UNIVERSITY OF VERMONT
Use of AAV replication machinery for improved protein production
ActiveUS20110119777A1Increase copy numberIncrease viable life-spanAnimal cellsBryophytesGMO PlantsGenetically modified animal
The present invention provides a method for enhanced production of a gene product of interest in a cell, using the AAV replication machinery. The present invention further relates to a cell for use in the method of the invention and a non-human transgenic animal or a transgenic plant comprising a cell of the invention.
Owner:UNIQURE IP BV
Methods of inhibiting photoreceptor apoptosis
ActiveUS20100226878A1Enhance photoreceptor survivalImprove survivalOrganic active ingredientsSenses disorderApoptosisCancer research
The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent FAS-mediated photoreceptor apoptosis.
Owner:RGT UNIV OF MICHIGAN
Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
ActiveUS7872048B2Reduces and decrease and inhibits activationInhibition is effectiveBiocideNervous disorderMedicineNeuron
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses
ActiveUS9963677B2Reduce cell deathFacilitated DiffusionPeptide/protein ingredientsViral antigen ingredientsT lymphocyteT cell
The present invention encompasses methods and compositions for the generation and use of cytotoxic T lymphocytes that target multiple viruses or that are specific for multiple tumor antigens. In specific embodiments, the generation methods employ use of certain cytokines to promote proliferation and reduce cell death in an activated T cell population and / or that employ a particular bioreactor having a gas permeable membrane.
Owner:WILSON WOLF MFG +1
Compositions and methods for tissue repair
InactiveUS20110305673A1Lower Level RequirementsMaximum protectionBiocideMicrobiological testing/measurementTissue repairDamages tissue
The invention features compositions comprising mesenchymal stem cells or multipotent stromal cells, agents secreted by such cells in culture, and methods featuring such cells for the repair or regeneration of a damaged tissue or organ. The present invention is based, at least in part, on the discovery that agents secreted by bone marrow mesenchymal stem cells or multipotent stromal cells (MSCs) were useful for the treatment or prevention of tissue damage related to ischemic injury (e.g., cerebral or cardiac ischemia).
Owner:UNIVERSITY OF VERMONT
Small molecule inhibitors of necrosis
InactiveUS20050131044A1Low toxicityReduced dosage requirementsOrganic active ingredientsBiocideCompound (substance)Cancer research
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Dipeptide apoptosis inhibitors and the use thereof
InactiveUS6949516B2Potent inhibitor of antiFas-induced lethalityRobust effectVectorsDipeptide ingredientsDipeptideApoptosis
The present invention is directed to novel dipeptides thereof, represented by the general Formula I: where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
Owner:CYTOVIA INC
Methods and compositions for treating conditions of the eye
InactiveUS20060204504A1Good curative effectReduced and delayed recurrenceBiocideSenses disorderPhotodynamic therapyNeutralizing antibody
Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.
Owner:MASSACHUSETTS EYE & EAR INFARY
Prepn process of acidophilic lactobacillus milk tablet
InactiveCN1672538AReduce cell deathHigh bacterial activityMilk preparationLactobacillus acidophilusLaboratory culture
The preparation process of acidophilic lactobacillus milk tablet adopts inducing mutation breeding method to breed high temperature mutant acidophilic lactobacillus strain, i. e., acidophilic lactobacillus LA201 strain. Meanwhile, matter capable of lowering the death rate of acidophilic lactobacillus is extracted from the Chinese herbal medicine extract liquid and microbe culture liquid. The breeding of high temperature acidophilic lactobacillus strain and the protecting agent make it possible to produce acidophilic lactobacillus milk tablet in available milk powder producing high temperature spray drying apparatus and conventional tabletting.
Owner:SHAANXI UNIV OF SCI & TECH
Use of Bone-Marrow Derived Stem Cells to Treat Ischemia
InactiveUS20090155220A1Restore peripheral circulationRescue lossBiocideMammal material medical ingredientsLimb ischemiaMedicine
Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue.
Owner:STEWARD RES & SPECIALTY PROJECTS
Method of tissue repair
InactiveUS20120301507A1Reduce cell deathEnhance cell viabilityBiocideMuscular disorderTissue repairRepair tissue
The present invention relates to methods of repairing tissue. More specifically, the present invention relates to methods of using cells and an implantable support for the repair of tissue defects, where the implantable support and cells are implanted into the tissue defect less than 2 hours after the cells are applied to the support.
Owner:ORTHOCELL PTY LTD
Buffer solution for electroporation and a method comprising the use of the same
InactiveUS20070110736A1High transfection efficiencyReduce cell deathBiocidePeptide/protein ingredientsElectroporationIon
The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an electric current and a buffer solution. The inventive buffer solution has a buffering capacity of at least 20 mmol*I−1*pH−1 and an ionic strength of at least 200 mmol* I−1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25 ° C. The use of a buffer solution of this type in the corresponding method allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in said buffer solution.
Owner:LONZA COLOGNE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com